pre-update Archives

Publication

Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients

To develop a population pharmacokinetic/pharmacodynamic model describing the relationship between motesanib exposure and tumor response…

CertaraNovember 1, 2010

Publication

Determination of a Quantitative Relationship Between Hepatic CYP3A51/3 and CYP3A4 Expression for Use in the Prediction of Metabolic Clearance in Virtual Populations

The creation of virtual populations allows the estimation of pharmacokinetic parameters, such as metabolic clearance…

CertaraNovember 1, 2010

Publication

Incorporating Human Dosimetry and Exposure into High-throughput In Vitro Toxicity Screening

Many chemicals in commerce today have undergone limited or no safety testing. To reduce the…

CertaraOctober 1, 2010

Publication

Randomised, Parallel-group, Multicenter, Multinational Phase 2 Study Comparing Edoxaban, an Oral Factor Xa Inhibitor, with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation

The primary objective of this study was to compare the safety of four fixed-dose regimens…

CertaraSeptember 10, 2010

Publication

Mechanistic Toxicokinetic Model for γ-Hydroxybutyric Acid: Inhibition of Active Renal Reabsorption as a Potential Therapeutic Strategy

γ-Hydroxybutyric acid (GHB), a drug of abuse, exhibits saturable renal clearance and capacity-limited metabolism. The …

CertaraSeptember 1, 2010

Publication

A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551

Pharmacokinetic-pharmacodynamic relationships are crucial in understanding a drug's arrhythmogenic potential. Models assist to quantitatively relate…

CertaraAugust 21, 2010

Publication

A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology

CertaraJuly 13, 2010

Publication

Confidence Assessment of Predicting Clinical Drug Interactions of Mechanism-based CYP3A Inhibitors Using Simcyp Time-based Approach and a Static Mathematic Model

Accurate prediction of the extent of mechanism-based CYP3A inhibition is critical in determining the timing…

CertaraJuly 1, 2010

Publication

Relationship Between Exposure to Sunitinib and Efficacy and Tolerability Endpoints in Patients with Cancer: Results of a Pharmacokinetic/Pharmacodynamic Meta-analysis

In this pharmacokinetic/pharmacodynamic meta-analysis, we investigated relationships between clinical endpoints and sunitinib exposure in patients…

CertaraJuly 1, 2010

Knowledge Base

What Does Clearance Mean?

Drug clearance is an extremely important topic in the science of pharmacokinetics. Drug clearance defines…

CertaraJune 13, 2010

pre-update

Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients

Determination of a Quantitative Relationship Between Hepatic CYP3A51/3 and CYP3A4 Expression for Use in the Prediction of Metabolic Clearance in Virtual Populations

Incorporating Human Dosimetry and Exposure into High-throughput In Vitro Toxicity Screening

Randomised, Parallel-group, Multicenter, Multinational Phase 2 Study Comparing Edoxaban, an Oral Factor Xa Inhibitor, with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation

Mechanistic Toxicokinetic Model for γ-Hydroxybutyric Acid: Inhibition of Active Renal Reabsorption as a Potential Therapeutic Strategy

A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551

A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology

Confidence Assessment of Predicting Clinical Drug Interactions of Mechanism-based CYP3A Inhibitors Using Simcyp Time-based Approach and a Static Mathematic Model

Relationship Between Exposure to Sunitinib and Efficacy and Tolerability Endpoints in Patients with Cancer: Results of a Pharmacokinetic/Pharmacodynamic Meta-analysis

What Does Clearance Mean?

Newsletter sign up

Quick links

Solutions

Contact